Cargando…
Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis
BACKGROUND: Although the clinical benefit of obtaining a remission in proteinuria in nephrotic patients with focal segmental glomerulosclerosis (FSGS) is recognized, the long-term value of maintaining it and the impact of relapses on outcome are not well described. METHODS: We examined the impact of...
Autores principales: | Jauhal, Arenn, Reich, Heather N, Hladunewich, Michelle, Barua, Moumita, Hansen, Bettina E, Naimark, David, Troyanov, Stéphan, Cattran, Daniel C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064837/ https://www.ncbi.nlm.nih.gov/pubmed/35948275 http://dx.doi.org/10.1093/ndt/gfac238 |
Ejemplares similares
-
Focal Segmental Glomerulosclerosis: Assessing the Risk of Relapse
por: Troyanov, Stéphan, et al.
Publicado: (2023) -
Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin
por: Hladunewich, Michelle A., et al.
Publicado: (2021) -
Exome sequencing and in vitro studies identified podocalyxin as a candidate gene for focal and segmental glomerulosclerosis
por: Barua, Moumita, et al.
Publicado: (2013) -
Remission of post-transplant focal segmental glomerulosclerosis with angiotensin receptor blockers
por: Bansal, S. B., et al.
Publicado: (2017) -
Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis
por: Barua, Moumita, et al.
Publicado: (2012)